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2Abstract
ALIX recruits ESCRT-III CHMP4 and is involved in membrane remodeling during 
endosomal receptor sorting, budding of some enveloped viruses and cytokinesis. We 
show that ALIX dimerizes via the middle domain (ALIX-V) in solution. Structural 
modeling based on small angle X-ray scattering (SAXS) data reveal an elongated crescent 
shaped conformation for dimeric ALIX lacking the proline rich domain (ALIXBRO1-V). 
Mutations at the dimerization interface prevent dimerization and induce an open 
elongated monomeric conformation of ALIX-V as determined by SAXS modeling. ALIX
dimerizes in vivo and dimeric ALIX co-localizes with CHMP4B upon co-expression. We 
show further that ALIX dimerization affects HIV-1 budding. C-terminally truncated 
activated CHMP4B retaining the ALIX binding site forms linear, circular and helical 
filaments in vitro, which can be bridged by ALIX. Our data suggest that dimeric ALIX 
represents the active form that interacts with ESCRT-III CHMP4 polymers and functions 
as a scaffolding protein during membrane remodeling processes. 
Keywords: ALIX, ESCRT-III, CHMP4, multivesicular body (MVB), budding, HIV, 
cytokinesis
3Introduction
Endosomal sorting processes determine the fate of plasma membrane receptors that are 
either recycled or delivered to the lysosome for degradation. (Gruenberg and Stenmark, 
2004; Hicke, 2001; Katzmann et al., 2002). An intricate network of protein interactions, 
which includes the sequential recruitment of ESCRT (Endosomal Sorting Complexes 
Required for Transport) complexes 0, I, II and III and associated molecules, regulates
endosomal protein sorting, vesicle formation and budding (Saksena et al., 2007) (Hurley, 
2008)(Lata et al., 2009). The accessory protein ALIX interacts with ESCRT-I Tsg101 
(Mahul-Mellier et al., 2006; Strack et al., 2003) as well as with all ESCRT-III CHMP4 
isoforms (Odorizzi et al., 2003)(Katoh et al., 2003)(Fisher et al., 2007)(McCullough et al., 
2008). ESCRT-III proteins polymerize on membranes (Babst et al., 2002)(Lin et al., 
2005) by forming filamentous (Ghazi-Tabatabai et al., 2008), circular (Hanson et al., 
2008) and helical tubular structures (Lata et al., 2008b) that act during membrane 
remodeling processes including membrane abscission (Lata et al., 2009). ESCRT-III 
proteins form inactive closed conformations in the cytosol and undergo polymerization 
and membrane targeting upon activation (Muziol et al., 2006)(Zamborlini et al., 
2006)(Shim et al., 2007)(Lata et al., 2008a)(Lata et al., 2008b). It is most likely that ALIX 
interacts only with an activated form of CHMP4 via a C-terminal CHMP4 binding motif 
(McCullough et al., 2008). Thus ALIX function must be linked to the role of ESCRT-III 
in membrane remodeling processes. In fact, ALIX itself might directly control changes in 
membrane structures (Matsuo et al., 2004)(Falguieres et al., 2008).
4ALIX was originally thought to be a homologue of yeast Bro1 that functions in 
receptor down regulation (Odorizzi et al., 2003)(Kim et al., 2005), but this role could not 
be confirmed (Cabezas et al., 2005)(Schmidt et al., 2004)(Doyotte et al., 2008).
ALIX is recruited to the budding process of some enveloped viruses such as HIV-
1 and equine infectious anemia virus (EIAV) (von Schwedler et al., 2003)(Strack et al., 
2003)(Martin-Serrano et al., 2003). Although EIAV budding is strictly dependent on 
ALIX (Martin-Serrano et al., 2003)(Strack et al., 2003), the EIAV late domain can be 
replaced by ESCRT-I Vps28, which provides access to ESCRT-III (Tanzi et al., 
2003)(Pineda-Molina et al., 2006). In contrast, ALIX is not sufficient to support HIV-1
budding in the absence of the Tsg101/ESCRT-I function (Garrus et al., 2001)(Martin-
Serrano et al., 2001). However, over-expression of ALIX or NEDD4 can rescue HIV-1 
late domain mutants (Usami et al., 2007)(Chung et al., 2008)(Usami et al., 2008).
Both ALIX and ESCRT-III family members are recruited to the midbody during 
cytokinesis (Carlton and Martin-Serrano, 2007)(Morita et al., 2007) where ALIX 
competes with Tsg101 for CEP55 interaction (Lee et al., 2008). Although CEP55 itself is 
not required for virus budding nor any endosome-related processes, virus budding and 
cytokinesis require ESCRT-III and VPS4 function.
ALIX is composed of three domains, an N-terminal Bro1-like domain (Kim et al., 
2005)(Fisher et al., 2007), which harbors the CHMP4B binding site (McCullough et al., 
2008), followed by the V-shaped middle domain composed of two three helical bundles 
that expose the retroviral late domain binding sites (Lee et al., 2007)(Fisher et al., 
2007)(Zhai et al., 2008); the third domain is a proline rich domain (PRD) that serves as a 
platform for multiple interaction partners including ESCRT-I Tsg101 (von Schwedler et 
5al., 2003)(Shibata et al., 2004)(Schmidt et al., 2004)(Chatellard-Causse et al., 2002) and 
CEP55 (Carlton and Martin-Serrano, 2007)(Morita et al., 2007)(Lee et al., 2008). PRD 
harbors the Alg-2 binding site (Suzuki et al., 2008), which links ALIX to apoptotic 
processes (Missotten et al., 1999)(Vito et al., 1999)(Trioulier et al., 2004)(Mahul-Mellier 
et al., 2006)(Mahul-Mellier et al., 2008). The scaffold function of ALIX is further 
underlined by its control of the actin cytoskeleton (Cabezas et al., 2005; Schmidt et al., 
2003)(Pan et al., 2006). Finally PRD regulates the function of ALIX by keeping it in an 
auto-inhibited state (Zhou et al., 2008b)(Zhou et al., 2008a). 
Here we show that ALIX dimerizes in vitro and in vivo via the V-domain, which 
helps to explain the dominant negative effect on HIV-1 budding observed for truncated 
ALIX constructs. We determine a main dimerization interface within the hinge region of 
the V-domain and present a low resolution model of dimeric ALIX based on SAXS 
analysis. Electron microscopy data indicate further that dimeric ALIX can bridge CHMP4 
filaments. Such a scaffolding function may thus help to position ESCRT-III on 
membranes and allow recruitment of a variety of effectors via its PRD region. 
Results
MALLS and SAXS analysis of ALIX. Both recombinant ALIXBro1-V and ALIXV elute 
from gel filtration columns in two distinct peaks. Analytical size exclusion 
chromatography in combination with multi angle laser light scattering (MALLS) revealed 
monomers for ALIXBro1-V and ALIXV as expected (Fisher et al., 2007)(Lee et al., 2007) as 
well as dimeric forms with average molecular weights of 158 ± 3 kDa for ALIXBro1-V
(Figure 1A) and 76 ± 3 kDa for ALIXV (Figure 1B). The ratio of monomers to dimers 
6purified from E. coli was ~ 5:1 for ALIXBro1-V and ~ 3:1 for ALIXV. Neither ALIXBro1-V
nor ALIXV monomers display a concentration dependent equilibrium with their respective 
dimers. Concentration of ALIXBro1-V and ALIXV monomers up to 20 mg/ml did not 
produce dimers, nor did dilution of dimers produce monomers as judged by gel filtration 
chromatography in agreement with analytical ultracentrifugation results (Fisher et al., 
2007). Thus no dimer to monomer exchange could be observed.
In order to understand the structural basis of ALIX dimerization, both ALIXBro1-V
monomers and dimers were analyzed by small angle X-ray scattering. The scattering 
intensity patterns corresponding to monomeric and dimeric ALIXBro1-V are shown in 
Figures 2A. The Guinier analysis revealed a radius of gyration (Rg) of 40.6 ± 0.1  !"#$!
monomeric and 81.2 ± 0.8  !"#$!%&'($&)!*+,-Bro1-V. Maximal protein dimensions (Dmax) 
of ~170  !"#$!./(!'#0#'($&)!!*+,-Bro1-V and ~300  !"#$!%&'($&)!ALIXBro1-V were found 
by the distance distribution function p(r) computed by a Fourier transformation of the 
scattering intensity (Figure 2B). This thus indicated that dimerization produced an
elongated shaped ALIXBro1-V. The shapes of the ALIX conformers were determined ab 
initio and reconstructed models of ALIXBro1-V fit the corresponding experimental data 
1&./! ./(! %&2)$(340)5! 6! #"! 789! 40%! 78:. The ab initio modeling produced an elongated 
shape with dimensions of ~ 40 x 60 x 145  !for monomeric ALIXBro1-V (Figure 2B, inset), 
which is largely consistent with the crystal structure of ALIXBro1-V (Fisher et al., 2007). 
Comparison of the experimental scattering curve and the one calculated from the 
ALIXBro1-V crystal structure revealed a discrepancy 6!#"!:8;8!Ab initio modeling of dimeric 
ALIXBro1-V yielded a crescent-shaped structure with a distance of ~ 270  !between the 
ends spanning the concave surface of the dimer (Figure 2C). 
7Mapping of the dimer interface. In order to analyze the mode of dimerization, D2O 
labeling of ALIXBro1-V coupled to peptide mapping by mass spectrometry analyses were 
applied. The resulting peptides were mapped onto the structure of monomeric ALIXBro1-V
and scored depending on an increase or decrease in D2O labeling. The most pronounced 
decrease in D2O labeling was observed for a peptide (aa 637-648) corresponding to a
potential hinge region between the two arms of ALIXV (Fisher et al., 2007)(Lee et al., 
2007), suggesting that this region is occluded in dimeric ALIX (Figure 3A). The labeling 
method also revealed higher accessibilities to D2O labeling in the dimer as compared to 
the monomer (Figure S1); this includes one region between the two arms of ALIXV 
(helices  11 and  18), several short helical segments within ALIXBro1 (helices  4,  5,  8 
and  10) and the long extended conformation spanning the concave surface of ALIXBro1 
connecting  10 and  11 (Figures 3B and S1). The data thus indicate a dimerization 
interface within ALIXV and potential conformational flexibility within ALIXBro1. 
Generation of an elongated “open” monomeric ALIXV conformation. In order to 
analyze the role of the ALIXV hinge region in dimerization, exposed residues within the 
segment 638-KMKQSNNE-645, that revealed differences in deuterium incorporation 
(Figure 3A) were changed to residues 638-EAAQSYKK-645 (ALIXVmut1) and to residues 
638-KMKQSYKK-645 (ALIXVmut2). Size exclusion chromatography (SEC) analyses 
showed that ALIXVmut1 eluted as a single peak at ~12 ml from a Superdex 200 column, a 
behavior which is different from the elution profile of ALIXV, which forms monomers 
and dimers (peaks at ~11.6 and ~13.5 ml) (Figure 4A). SEC of ALIX-Vmut2 produced two
new peaks eluting at ~11.2 and at 12.6 ml (Figure 4A). Applying MALLS, the single peak 
8of ALIXVmut1 was determined to correspond to a molecular weight of ~ 42 kDa and the 
two peaks obtained for ALIXVmut2 were determined to correspond to monomeric (~42 
kDa) and dimeric forms (~86 kDa) of ALIXV (Figure 4B). Although ALIXVmut2 can still 
form dimers, the elution positions determined by SEC indicate that both monomers and 
dimers exhibit a larger hydrodynamic radius as compared to wild type ALIXV.  
Monomeric ALIXVmut1 was further analyzed by small angle X-ray scattering and 
compared to wild type ALIXV. The Guinier analysis of the scattering curves (Figure 5A) 
revealed a radius of gyration (Rg) of 53.6  <!40%!'4=&'4>!3$#.(&0!%&'(02&#02!?@max) of 
~190 !1($(! )4>)A>4.(%!B5! ./(! %&2.40)(!%&2.$&BA.&#0! "A0).&#0!3?$C! "#$!ALIXVmut1 (Figure 
5B). Wild type ALIXV  SAXS analysis produced a smaller Rg of 33.4  !and a smaller 
Dmax of ~ 125  !?D&EA$(!FGC! )#0"&$'&0E! ./4.! ./(! 'A.4.&#02! $(2A>.(%! &0! 40! (>#0E4.(%!
conformation. Comparison of the theoretical scattering curve derived from the ALIXV
crystal structure (pdb 2ojq) and the experimental data (Figure 5A) indicated a high 
%&2)$(340)5! 6!H!F<! 2AEE(2.&0E! ./4.! )$52.4>>&I4.&#0!>#)J(%! ./(!K-domain in the observed 
conformation.
The shape of the ALIXVmut1 was determined ab initio and resulted in a 170 Å long 
conformation (Figure 5C). The reconstructed average model of ALIXVmut1 fit the 
)#$$(23#0%&0E!(=3($&'(0.4>!%4.4!1&./!./(!%&2)$(340)5!6!#"!78FL!?D&EA$(!5A). The model 
suggests an open conformation of ALIXV, whereas one arm of ALIXV needs to rotate ~ 
140º to fit the elongated envelope (Figure 5D). The monomeric conformation of 
ALIXVmut1 indicates that the mutations not only prevent dimerization but may also 
stabilize an open ALIXV conformation. Together with the SAXS data on dimeric 
ALIXBro1-V, these results provide support for a dimerization model, whereas opening of 
9ALIXV conformation (as observed in the crystal structures) precedes dimerization. This 
might entail an anti-parallel association of the ALIXV arms producing an arrangement that 
positions the Bro1 domains at the extreme ends of the arch-shaped ALIXBro1-V dimer 
model (Figure 5E). 
ALIXBro1-V expression in mammalian cells induces dimerization. We used the split
YFP complementation assay to test ALIX dimerization in cells (Michnick et al., 2007). 
Both N-terminal YFP and C-terminal YFP halves were fused to the C-terminus of 
ALIXBro1-V and expressed in HEK293 cells. Fluorescence analyses by confocal 
microscopy revealed detection of YFP fused to ALIXBro1-V only when both fusion proteins 
were co-expressed (Figure 6A, right panel). This thus indicates that ALIXBro1-V forms
dimers when expressed in mammalian cells, which mainly localize to the cytoplasm.
Both ALIXV monomers and dimers interact with a late domain peptide. In order to 
determine whether dimeric ALIX might affect enveloped virus budding, isothermal 
calorimetry was performed to determine the interaction of ALIXV with a peptide derived 
from EIAV Gag p9. This revealed equilibrium dissociation constants (KD) of 5 +/- 0.3 MN!
for monomeric ALIXV, consistent with the reported interactions of ALIX monomers and 
retroviral late domains (Fisher et al., 2007; Lee et al., 2007; Zhai et al., 2008) and of 8 +/-
1.2 MN!"#$!%&'($&)!ALIXV. Thus dimeric ALIX constitutes a target for retroviral Gag. 
ALIX dimerization is important for HIV-1 budding. We tested the effect of ALIX 
dimerization on HIV-1 budding since RFP-ALIXV-PRD expression has been shown to exert 
a dominant negative effect on HIV-1 particle release (Strack et al., 2003). Expression of 
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RFP-ALIXVmut2-PRD (still able to form dimers in solution) in HIV-1 infected cells had no 
consequence on the dominant negative effect imposed by RFP-ALIXV-PRD. Particle 
release was similarly reduced as in case of wild type RFP-ALIXV-PRD expression (Figure 
7B, left panel, lanes 2 and 3). In contrast, expression of RFP-ALIXVmut1-PRD reversed the 
dominant negative effect of the wild type because no effect on particle release was 
observed (Figure 7A, left panel lane 3). Cellular expression levels of RFP-ALIXV-PRD
constructs were comparable (Figure 7C) as well as the presence of intracellular Gag 
products. This thus indicates that the potential to dimerize is required for this ALIX 
construct in order to exert a dominant negative effect, which confirms a physiological role 
for ALIX dimerization.
ALIX binds to CHMP4 polymers. We next analyzed whether ALIXBro1-V interacts with 
CHMP4 polymers. Both ALIXBro1-V conformers are found in the upper fractions of a 
sucrose gradient consistent with their monodispersity in solution (Figure 8A and B). In 
contrast, C-terminally deleted CHMP4B fused to MBP (MBP-CHMP4BOP) forms 
polymers found in the bottom fractions of a sucrose gradient (Figure 8C). Since MBP-
CHMP4BOP lacks the ALIX binding site, we fused the ALIX binding site motif 
(McCullough et al., 2008) via a linker to MBP-CHMP4BOP (MBP-CHMP4BOPQ*+,-). 
MBP-CHMP4BOPQ*+,- localizes to the upper and to the bottom fractions of a sucrose 
gradient (Figure 8D) similar to MBP-CHMP4BOP. Removal of MBP by TEV cleavage 
renders all of CHMP4BOPQ*+,- polymeric and is thus present in the bottom of a sucrose 
gradient (Figure 8E). Incubation of MBP-CHMP4BOPQ*+,- with either monomeric or 
dimeric ALIXBro1-V redistributes ALIXBro1-V from the upper fractions to the bottom 
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fractions upon sucrose gradient centrifugation (Figures 8F and G). Since both MBP-
CHMP4BOPQ*+,- and ALIXBro1-V migrate at the same positions on SDS-PAGE their 
presence is confirmed by western blot analyses (Figure 8H). Similar complex formation is 
observed when CHMP4BOPQ*+,- (MBP removed by TEV cleavage) is incubated with 
monomeric or dimeric ALIXBro1-V (Figure 8 I and J). 
The bottom fractions of the single proteins and the complexes were analyzed by 
negative staining electron microscopy. MBP-CHMP4BOP assembles into ring-like 
structures of varying diameters (~ 40 to ~ 70 nm) (Figure 9A). The width of the rings 
measures ~25Å and the length of the potential repeating units is ~40 Å (Figure 9H, left 
panel). Thicker appearing (~100 Å) more filamentous structures are formed by MBP-
tagged CHMP4BOPQ*+,- (Figure 9B). Removal of MBP from CHMP4BOPQ*+,- reveals 
more defined filaments, which have diameters of ~100 Å (Figure 9C). These filaments 
can be decorated with monomeric ALIXBro1-V, which render the surface to appear fuzzy 
(Figure 9D). Dimeric ALIXBro1-V bridges two CHMP4BOPQ*+,- filaments and generates 
ladders made up of “legs”of CHMP4B and “rungs” of ALIXBro1-V (Figure 9E).  The rungs 
are ~400Å wide and are ~100 Å longer than dimeric ALIXBro1-V in solution since SAXS
analysis revealed a Dmax of ~300Å (Figure 2B). The presence of these structures was 
further confirmed by cryo electron microscopy imaging. The cryo images reveal ~30 Å 
thick circular arrays (Figure 9F and S2) and ring-like structures for CHMP4BOPQ*+,-
(Figure 9G). The length of a potential repeating unit in the rings measures ~50Å, similar 
to the negatively stained images (Figure 9H, left and right panel). This thus suggests that 
the filaments or rings are most likely constructed by a head to tail interaction of single 
CHMP4B molecules. When these structures are decorated with dimeric ALIXBro1-V linear 
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and spiral structures are observed with dimeric ALIXBro1-V spanning a distance of ~ 450Å,
with a spacing of ~50 Å between rungs (Figure 9I). The cryo images also show mostly 
ladders as observed by negative staining although it cannot be excluded that some cross 
linking between ladders occurs (Figure S3). The difference in spacing observed by 
negative staining and cryo EM might be either due to the fact that (i) binding of ALIXBro1-
V is sensitive to the heavy atom solution used for negative staining or due to the fact that 
(ii) ALIXBro1-V, which is in contact with the carbon is embedded with heavy atom and 
visualized, a phenomenon observed previously (Gaillard et al., 2008). Each 
CHMP4BOPQALIX monomer extends the ALIX binding site from the predicted core 
CHMP4 structure by ~30 amino acids that could span up to ~100 Å in an extended 
conformation. The extension of the ALIX binding site peptide from the CHMP4B 
polymer and the positions of the CHMP4B binding sites in the ALIXBro1-V dimer ( ~230 Å 
apart) cannot explain the observed spacing between two CHMP4B filaments induced by 
dimeric ALIXBro1-V interaction. The flexible linkage of a ~300Å long ALIXBro1-V dimer 
would not produce the rather evenly spaced CHMP4 filaments. It is thus conceivable that 
further conformational changes induced by binding to CHMP4B filaments have to occur 
that produce longer ALIXBro1-V dimers as indicated by the electron microscopy images. 
Such changes might include the long extended conformation spanning the whole concave 
side of ALIXBro1 and connecting ALIXBro1 helix 10 and ALIXV helix 11. Notably part of 
this region becomes more accessible to D2O exchange in the dimer as compared to the 
monomer (Figure 3B). The preferred detection of ladders might be explained by 
conformational constraints imposed by the cross linking of two CHMP4 filaments by 
13
ALIXBro1-V, since the ALIX binding site could be positioned towards the interior of the 
CHMP4B ladder. 
Cellular localization of activated CHMP4B and ALIXBro1-V. To determine whether 
activated CHMP4BOPQ*+,- localizes to membranes and/or induces membrane remodeling 
(Hanson et al., 2008) in the absence of other ESCRT factors, CHMP4BOPQ*+,- was 
expressed with a C-terminal flag-tag in HEK293 cells. Immunostaining revealed that 
CHMP4BOPQ*+,- concentrates in inclusions that appear to be close to the plasma 
membrane (Figure 6B) similar to a previous report (Lin et al., 2005); upon co-expression 
with dimeric ALIXBro1-V fused to the two YFP Venus halves most of ALIXBro1-V is also 
recruited into CHMP4BOPQ*+,- positive inclusions (Figure 6C), thus indicating that 
dimeric ALIX targets ESCRT-III CHMP4 polymers in vivo.  
Discussion
ALIX is a cellular adaptor protein that engages in a number of seemingly unrelated 
processes ranging from endosomal trafficking (Saksena et al., 2007), apoptosis (Vito et 
al., 1999)(Missotten et al., 1999), cytoskeleton reorganization (Cabezas et al., 2005)
(Pan et al., 2006), retrovirus budding (Usami et al. 2009) and cytokinesis (Carlton and 
Martin-Serrano, 2007)(Morita et al., 2007). Thus ALIX underlies tight regulation that 
requires the C-terminal proline-rich region (PRD) harboring numerous protein-protein 
interacting motifs important for function and regulation of Alix (Odorizzi, 2006). PRD 
keeps ALIX in an auto-inhibited conformation (Zhou et al., 2008b)(Zhou et al., 
2008a)(Lazert et al., 2008),which suggests that ALIX has to be activated. Our data 
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indicate that activation of ALIX induces dimerization. Oligomerization and 
dimerization of ALIX was observed previously(Munshi et al., 2007)(Fisher et al., 2007), 
and we confirm that the V-domain is sufficient for dimerization. It is, however, yet 
unclear which signal induces dimerization in vitro and in vivo. We show that both 
ALIXBro1-V and ALIXV monomers and dimers are stable entities and do not exchange in 
vitro (Fisher et al., 2007).
ALIXBro1-V contains a Bro1 domain (Kim et al., 2005) and a central V-shaped 
domain (Fisher et al., 2007)(Lee et al., 2007). Bro1 interacts with ESCRT-III CHMP4 
and the V-domain harbors the retroviral late domain binding site (Kim et al., 2005)(Zhai 
et al., 2008)(McCullough et al., 2008)(Lee et al., 2007). SAXS analyses of dimeric 
ALIXBro1-V revealed an elongated ALIXBro1-V structure that measures ~ twice the length 
of monomeric ALIXBro1-V. Interestingly, the shape of dimeric ALIXBro1-V resembles that 
of BAR domains such as amphipysin (Peter et al., 2004) and endophilin (Weissenhorn, 
2005). Although we observe membrane interaction of ALIXBro1-V in vitro (data not 
shown) no specific membrane remodeling effect could be assigned. Thus, the 
architecture might be preferentially used to bridge two effector molecules.
Since no concentration dependent equilibrium between monomers and dimers 
could be detected (Fisher et al., 2007), dimer formation must include specific 
conformational changes. Hydrogen/deuterium exchange experiments coupled to mass 
spectrometry peptide mapping revealed several sites of conformational flexibility, 
notably not only within the V-dimerization domain but also within the Bro1 domain. 
Such conformational flexibility is consistent with the structure of ALIXBro1-V, which 
shows that Bro1 and V are connected via a short linker as well as some degree of 
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flexibility between the two arms of the V domain (Fisher et al., 2007). The mutagenesis 
studies suggest that the two arms of ALIXV are connected via a hinge region, which is 
stabilized in the crystal structure by a salt bridge between K640 and E650, that also 
hydrogen bonds to N400 (Lee et al., 2007)(Fisher et al., 2007). A set of mutations 
within this region including K640 destabilized the monomer and in addition prevented 
dimer formation. Since the hydrogen/deuterium exchange experiments suggest that this 
region is more protected in dimeric ALIXBro1-V, changes within this region might 
prevent important dimer contacts. Alternatively, the mutations could artificially stabilize 
an open monomer conformation that itself prevents dimerization. The latter possibility 
is supported by the SAXS model of ALIXVmut1 that indicates an elongated form of 
ALIXV;the crystal structure of ALIXV would fit into the SAXS envelope when one arm 
of the V-domain is rotated by ~ 140º. Based on these data we suggest the following
dimerization model: Displacement of PRD serves as a first signal to release auto-
inhibition (Zhou et al., 2008b)(Zhou et al., 2008a), a second signal then leads to an 
opening of the V-domain and subsequent  anti-parallel dimerization via the V-domain  
arms (Figure 5E). 
Expression of truncated ALIX conformers such ALIXV-PRD and ALIXV have 
been shown to induce dominant negative effects on retroviral budding (Strack et al., 
2003)(Munshi et al., 2007). We show that such an effect is inhibited in the presence of 
the dimerization mutations since RFP-ALIXVmut1-PRD expression is no longer a dominant 
negative inhibitor of HIV-1 budding. It is thus conceivable that truncated forms of 
ALIX which retain the V dimerization domain form heterodimers with endogenous 
ALIX. The function of such mixed dimers might be compromised by the lack of adaptor
16
protein binding which might position the complex within the correct network of 
interactions required to trigger down stream effects. Thus ALIXBro1-Vmut1 that no longer 
dimerizes has no effect on the budding process. The dominant negative effect may 
further depend on the interaction with Gag, since dimeric ALIXV interacts with a EIAV 
late domain peptide with a similar Kd as reported for monomeric ALIXV (Munshi et al., 
2007)(Fisher et al., 2007).
Several lines of evidence suggest that ALIX functions directly on membranes. 
Firstly, ALIX localizes to the plasma and endosomal membranes (Welsch et al., 2006). 
Secondly, it plays a role in the formation of internal endosomal membranes in 
conjunction with lysobiphosphatidic acid (LBPA) (Matsuo et al., 2004). Thirdly, 
expression of ALIXV-PRD was shown to induce cytoplasmic vacuolization into tubulo-
vesicular structures that co-localize with ALIX (Chatellard-Causse et al., 2002); this 
effect might be also due to the formation of mutant-wild type ALIX heterodimers that 
lack important binding sites. Fourthly, it is recruited by interaction with ESCRT-III 
CHMP4, which acts at membranes (Katoh et al., 2003)(von Schwedler et al., 
2003)(Strack et al., 2003). ESCRT-III proteins CHMP2A and CHMP3 have been shown 
to assemble into heteromeric helical polymers that may catalyze late budding steps such 
as abscission (Lata et al., 2008b). Similarly, ESCRT-III CHMP4 expression in 
mammalian cells was shown to form circular filaments (Hanson et al., 2008) consistent 
with ring-like and filamentous structures of CHMP4 observed in vitro (Ghazi-Tabatabai 
et al., 2008). Here we show that activated CHMP4, which most likely requires 
detachment of the C-terminal MIM domain from the N-terminal core (Shim et al., 
2007)(Lata et al., 2008a), forms linear filaments as well as spiral and ring-like 
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structures. The ring and spiral CHMP4B structures (Figure 9A, F, G) are most likely 
formed by head to tail interactions of single CHMP4B molecules. Thus CHMP4B 
polymerization differs from CHMP2A-CHMP3 polymerization since it does not require 
homo- or heterodimerization. The latter is consistent with the excess of CHMP4 over its 
potential binding partner CHMP6 present in the yeast ESCRT-III complex (Saksena et 
al., 2009). The spiral CHMP4B structures observed here might thus reflect the polymer 
structures observed in vivo (Hanson et al., 2008) that drive early steps in HIV-1 
assembly and budding (Carlson et al., 2008).
Both ALIX and CHMP4B are present at the midbody (Carlton and Martin-
Serrano, 2007)(Morita et al., 2007) and CHMP4-ALIX-CEP55 interactions are essential 
for midbody formation (Carlton et al., 2008). Since dimeric ALIXBro1-V bridges 
preferentially two CHMP4B filaments or spirals in vitro, ALIX could support CHMP4 
polymer positioning on membranes during viral budding as well as at the midbody
supported by CEP55 (Carlton et al., 2008)(Morita et al., 2007). ALIX polymerizes itself
(Carlton et al., 2008) whereas dimeric ALIX might constitute the the building block for 
CHMP4 induced polymerization at budding sites. Because ALIXBro1-V lacks the 
multimerization site (Carlton et al., 2008), we do not observe ALIX polymers in vitro. 
Polymerization of ALIX is further supported by the stochiometry of ESCRT-III. 
ESCRT-III contains multiple copies of CHMP4 (Teis et al., 2008)(Saksena et al., 2009)
supporting CHMP4 polymerization which in turn provides multiple binding sites for 
ALIX polymerization. 
The formation and physiological role of ALIX dimers was further proven by 
using a YFP complementation assay (Michnick et al., 2007). Dimeric ALIXBro1-V-YFP 
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is mostly found in the cytosol, indicating that dimerization is not sufficient for 
membrane targeting. When it is expressed together with CHMP4BOP-ALIX both 
structures co-localize in large inclusions, demonstrating that polymeric CHMP4B 
recruits dimeric ALIX in vivo. Thus our data suggest that recruitment of activated 
ESCRT-III CHMP4B entails the function of dimeric ALIXBro1-V. This might help to 
position ESCRT-III at sites of membrane remodeling by providing access to the 
cytoskeleton (Cabezas et al., 2005)(Pan et al., 2006).
Experimental procedures
Protein expression and purification
Cloning, expression, purification and SEC characterization including MALLS of ALIX 
and CHMP4B constructs is described in the supporting online material (SOM). 
Small Angle Scattering Data Collection and Analysis
The synchrotron radiation X-ray scattering data were collected on the X33 SAXS 
beam line (DESY and EMBL, Hamburg) (Koch and Bordas, 1983; Roessle et al., 2007)
and at the ESRF beam line ID02  (Grenoble). A MAR345 image plate with online readout 
(MarResearch, Germany) was used at a sample - detector distance of 2.4 m covering the 
range of momentum transfer 0.1 < s < 4.5 nm-1 (s = 4R!sin(S)/T<!1/($(!S!&2!./(!2)4..($&0E!
40E>(! 40%! T! U! V87F! 0'! &2! ./(! --ray wavelength). The s-axis was calibrated by the 
scattering pattern of Silver-behenate salt (d-spacing 5.84 nm). The scattering patterns 
from ALIXBro1-V in the monomeric and dimeric phase were measured at protein 
concentrations of 10.0, 7.4, 5.0 and 2 mg/ml and 2.9, 1.4 and 1.2 mg/ml, respectively. 
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ALIXVmut1 was measured at a concentration of 7mg/ml at the ESRF (Grenoble) beam line 
ID02. Further details on SAXS data analysis and model calculation are described in SOM. 
Mammalian expression constructs andHIV-1 release assay.
The mammalian expression vector pDSRed2-C1/AIP1!BRO, encoding ALIXV-PRD, with the 
N-terminal Bro1-domain replaced by RFP (Strack et al., 2003), was mutated to produce 
both V-domain dimerization mutants (RFP-ALIXVmut1-PRD and RFP-ALIXVmut2-PRD) using 
standard procedures. See SOM for further details.
For indirect immunofluorescence detection of CHMP4B!C_ALIX its cDNA was 
cloned with a C-terminal Flag-epitope into the mammalian expression vector pCAGGS by 
PCR using pBADM41-CHMP4B!C_ALIX as a template. The plasmid was transfected alone 
or together with ALIXBro1-V fused to the N-terminal halve of YFP and the C-terminal 
halve of YFP in HEK293 cells using TransIT (Mirus) and OptiMem (Invitrogen) 
according to the manufacturer's instructions. For further details see SOM.
Hydrogen/deuterium (H/D) exchange mass spectrometry (MS)
Deuterium labeling of monomeric and dimeric ALIXBro1-V was carried out by 20-fold 
dilution of the protein samples in deuterated buffer (5mM Hepes, 100mM NaCl in D2O, 
pD 7.6) followed by incubation at 4ºC for different time intervals (from 10 s to 30 min). 
The reaction was quenched by lowering the pD to 2.1 with 0.1 M HCl solution. Pepsin 
(Sigma-Aldrich) digestion was performed at 4ºC and pH 2.5 for 2 min in 0.1 M HCl and a 
protein:protease ratio of 1:1 (w/w). Further details are reported in SOM. 
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Electron microscopy
CHMP4BOP-Alix and ALIXBro1-V were purified by sucrose gradient centrifugation (Lata et 
al., 2008b) and samples present in the bottom fractions were analyzed by electron 
microscopy using negative staining with uranyl acetate or sodium silicotungstate (pH 7.0) 
(Lata et al., 2008b). For cryo electron microscopy CHMP4BOP-Alix alone or in complex 
with ALIXBro1-V the sucrose was removed and W!M>!sample were loaded onto a Quantifoil 
R2/1 holey grid (Quantifoil Micro Tools GmbH, Germany). The grids were treated and 
observed using a JEOL 2010 FEG electron microscope (Schoehn et al., 2008).
Acknowledgements
We thank Dr. A. Grichine from the Institute Albert Bonnoit (Grenoble) microscopy 
platform for his assistance and Dr. B. Blot and C. Chatellard-Causse for helpful 
discussions. This work was supported by the ANRS (WW), the DFG SPP1175 (WW), the 
EU FP6 Program (SAXIER, RIDS 011934) (DS, MR), the National Institute of Allergy 
and Infectious Diseases (R37AI029873 to HG), the ANR (“Jeune Chercheur”, G.S.), the 
French Ministry of Research (C.M.) and postdoctoral fellowships from the European 
Molecular Biology Organization (S.L. and B. H.) and the International Human Frontier 
Science Program Organization (S.L.). The content is solely the responsibility of the 
authors and does not necessarily represent the official views of the National Institute of 
Allergy and Infectious Diseases or the National Institutes of Health. The HIV-1 p24 
monoclonal antibody (183-H12-5C) (provided by Drs. Bruce Chesebro and Kathy 
Wehrly) was obtained through the AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH. 
21
References
Babst, M., Katzmann, D. J., Estepa-Sabal, E. J., Meerloo, T., and Emr, S. D. (2002). 
ESCRT-III: An endosome-associated heterooligomeric protein complex required for 
MVB sorting. Dev Cell 3, 271-282.
Cabezas, A., Bache, K. G., Brech, A., and Stenmark, H. (2005). Alix regulates cortical 
actin and the spatial distribution of endosomes. J Cell Sci 118, 2625-2635.
Carlson, L. A., Briggs, J. A., Glass, B., Riches, J. D., Simon, M. N., Johnson, M. C., 
Muller, B., Grunewald, K., and Krausslich, H. G. (2008). Three-dimensional analysis 
of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. 
Cell Host Microbe 4, 592-599.
Carlton, J. G., Agromayor, M., and Martin-Serrano, J. (2008). Differential requirements 
for Alix and ESCRT-III in cytokinesis and HIV-1 release. Proc Natl Acad Sci U S A
105, 10541-10546.
Carlton, J. G., and Martin-Serrano, J. (2007). Parallels between cytokinesis and retroviral 
budding: a role for the ESCRT machinery. Science 316, 1908-1912.
Chatellard-Causse, C., Blot, B., Cristina, N., Torch, S., Missotten, M., and Sadoul, R. 
(2002). Alix (ALG-2-interacting protein X), a protein involved in apoptosis, binds to 
endophilins and induces cytoplasmic vacuolization. J Biol Chem 277, 29108-29115.
Chung, H. Y., Morita, E., von Schwedler, U., Muller, B., Krausslich, H. G., and 
Sundquist, W. I. (2008). NEDD4L overexpression rescues the release and infectivity of 
human immunodeficiency virus type 1 constructs lacking PTAP and YPXL late 
domains. J Virol 82, 4884-4897.
Doyotte, A., Mironov, A., McKenzie, E., and Woodman, P. (2008). The Bro1-related 
protein HD-PTP/PTPN23 is required for endosomal cargo sorting and multivesicular 
body morphogenesis. Proc Natl Acad Sci U S A 105, 6308-6313.
Falguieres, T., Luyet, P. P., Bissig, C., Scott, C. C., Velluz, M. C., and Gruenberg, J. 
(2008). In vitro budding of intralumenal vesicles into late endosomes is regulated by 
Alix and Tsg101. Mol Biol Cell 19, 4942-4955.
Fisher, R. D., Chung, H. Y., Zhai, Q., Robinson, H., Sundquist, W. I., and Hill, C. P. 
(2007). Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus 
budding. Cell 128, 841-852.
Gaillard, J., Neumann, E., Van Damme, D., Stoppin-Mellet, V., Ebel, C., Barbier, E., 
Geelen, D., and Vantard, M. (2008). Two microtubule-associated proteins of 
Arabidopsis MAP65s promote antiparallel microtubule bundling. Mol Biol Cell 19, 
4534-4544.
Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., 
Wang, H. E., Wettstein, D. A., Stray, K. M., Cote, M., Rich, R. L., et al.(2001). 
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell
107, 55-65.
Ghazi-Tabatabai, S., Saksena, S., Short, J. M., Pobbati, A. V., Veprintsev, D. B., 
Crowther, R. A., Emr, S. D., Egelman, E. H., and Williams, R. L. (2008). Structure and 
disassembly of filaments formed by the ESCRT-III subunit Vps24. Structure 16, 1345-
1356.
Gruenberg, J., and Stenmark, H. (2004). The biogenesis of multivesicular endosomes. Nat 
Rev Mol Cell Biol 5, 317-323.
22
Hanson, P. I., Roth, R., Lin, Y., and Heuser, J. E. (2008). Plasma membrane deformation 
by circular arrays of ESCRT-III protein filaments. J Cell Biol 180(2), 389-402.
Hicke, L. (2001). Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2, 195-201.
Hurley, J. H. (2008). ESCRT complexes and the biogenesis of multivesicular bodies. Curr 
Opin Cell Biol 20, 4-11.
Katoh, K., Shibata, H., Suzuki, H., Nara, A., Ishidoh, K., Kominami, E., Yoshimori, T., 
and Maki, M. (2003). The ALG-2-interacting protein Alix associates with CHMP4b, a 
human homologue of yeast Snf7 that is involved in multivesicular body sorting. J Biol 
Chem 278, 39104-39113.
Katzmann, D. J., Odorizzi, G., and Emr, S. D. (2002). Receptor downregulation and 
multivesicular-body sorting. Nature Reviews Molecular Cell Biology 3, 893-905.
Kim, J., Sitaraman, S., Hierro, A., Beach, B. M., Odorizzi, G., and Hurley, J. H. (2005). 
Structural basis for endosomal targeting by the Bro1 domain. Dev Cell 8, 937-947.
Koch, M. H. J., and Bordas, J. (1983). X-ray diffraction and scattering on disordered 
systems using synchrotron radiation. Nucl Instrum Methods 208,, 461-469.
Lata, S., Roessle, M., Solomons, J., Jamin, M., Gottlinger, H. G., Svergun, D. I., and 
Weissenhorn, W. (2008a). Structural basis for autoinhibition of ESCRT-III CHMP3. J 
Mol Biol 378, 818-827.
Lata, S., Schoehn, G., Jain, A., Pires, R., Piehler, J., Gottlinger, H. G., and Weissenhorn, 
W. (2008b). Helical structures of ESCRT-III are disassembled by VPS4. Science 321, 
1354-1357.
Lata, S., Schoehn, G., Solomons, J., Pires, R., Gottlinger, H.G. and Weissenhorn, W. 
(2009) Structure and function of ESCRT-III. Biochem Soc Trans, 37, 156-160.
Lazert, C., Chazal, N., Briant, L., Gerlier, D., and Cortay, J. C. (2008). Refined study of 
the interaction between HIV-1 p6 late domain and ALIX. Retrovirology 5, 39.
Lee, H. H., Elia, N., Ghirlando, R., Lippincott-Schwartz, J., and Hurley, J. H. (2008). 
Midbody targeting of the ESCRT machinery by a noncanonical coiled coil in CEP55. 
Science 322, 576-580.
Lee, S., Joshi, A., Nagashima, K., Freed, E. O., and Hurley, J. H. (2007). Structural basis 
for viral late-domain binding to Alix. Nat Struct Mol Biol 14, 194-199.
Lin, Y., Kimpler, L. A., Naismith, T. V., Lauer, J. M., and Hanson, P. I. (2005). 
Interaction of the mammalian endosomal sorting complex required for transport 
(ESCRT) III protein hSnf7-1 with itself, membranes, and the AAA+ ATPase SKD1. J 
Biol Chem 280, 12799-12809.
Mahul-Mellier, A. L., Hemming, F. J., Blot, B., Fraboulet, S., and Sadoul, R. (2006). 
Alix, making a link between apoptosis-linked gene-2, the endosomal sorting 
complexes required for transport, and neuronal death in vivo. J Neurosci 26, 542-549.
Mahul-Mellier, A. L., Strappazzon, F., Petiot, A., Chatellard-Causse, C., Torch, S., Blot, 
B., Freeman, K., Kuhn, L., Garin, J., Verna, J. M., et al.(2008). Alix and ALG-2 are 
involved in TNF-R1 induced cell death. J Biol Chem 283(50), 34954-65.
Martin-Serrano, J., Yarovoy, A., Perez-Caballero, D., and Bieniasz, P. D. (2003). 
Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by 
using alternative adaptor proteins. Proc Natl Acad Sci U S A 100, 12414-12419.
Martin-Serrano, J., Zang, T., and Bieniasz, P. (2001). HIV-1 and Ebola virus encode 
small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate 
egress. Nat Med 7, 1313 - 1319.
23
Matsuo, H., Chevallier, J., Mayran, N., Le Blanc, I., Ferguson, C., Faure, J., Blanc, N. S., 
Matile, S., Dubochet, J., Sadoul, R., et al.(2004). Role of LBPA and Alix in 
multivesicular liposome formation and endosome organization. Science 303, 531-534.
McCullough, J., Fisher, R. D., Whitby, F. G., Sundquist, W. I., and Hill, C. P. (2008). 
ALIX-CHMP4 interactions in the human ESCRT pathway. Proc Nat Acad Sci USA
105, 7687-7691.
Michnick, S. W., Ear, P. H., Manderson, E. N., Remy, I., and Stefan, E. (2007). Universal 
strategies in research and drug discovery based on protein-fragment complementation 
assays. Nat Rev Drug Discov. 6, 569-582.
Missotten, M., Nichols, A., Rieger, K., and Sadoul, R. (1999). Alix, a novel mouse 
protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 
(ALG-2) protein. Cell Death Differ 6, 124-129.
Morita, E., Sandrin, V., Chung, H. Y., Morham, S. G., Gygi, S. P., Rodesch, C. K., and 
Sundquist, W. I. (2007). Human ESCRT and ALIX proteins interact with proteins of 
the midbody and function in cytokinesis. EMBO J 26, 4215-4227.
Munshi, U. M., Kim, J., Nagashima, K., Hurley, J. H., and Freed, E. O. (2007). An Alix 
fragment potently inhibits HIV-1 budding: characterization of binding to retroviral 
YPXL late domains. J Biol Chem 282, 3847-3855.
Muziol, T., Pineda-Molina, E., Ravelli, R. B., Zamborlini, A., Usami, Y., Gottlinger, H., 
and Weissenhorn, W. (2006). Structural basis for budding by the ESCRT-III factor 
CHMP3. Dev Cell 10, 821-830.
Odorizzi, G. (2006). The multiple personalities of Alix. J Cell Sci 119, 3025-3032.
Odorizzi, G., Katzmann, D. J., Babst, M., Audhya, A., and Emr, S. D. (2003). Bro1 is an 
endosome-associated protein that functions in the MVB pathway in Saccharomyces 
cerevisiae. Journal of Cell Science 116, 1893-1903.
Pan, S., Wang, R., Zhou, X., He, G., Koomen, J., Kobayashi, R., Sun, L., Corvera, J., 
Gallick, G. E., and Kuang, J. (2006). Involvement of the conserved adaptor protein 
Alix in actin cytoskeleton assembly. J Biol Chem 281, 34640-34650.
Peter, B. J., Kent, H. M., Mills, I. G., Vallis, Y., Butler, P. J. G., Evans, P. R., and 
McMahon, H. T. (2004). BAR Domains as Sensors of Membrane Curvature: The 
Amphiphysin BAR Structure. Science 303, 495-499.
Pineda-Molina, E., Belrhali, H., Piefer, A. J., Akula, I., Bates, P., and Weissenhorn, W. 
(2006). The crystal structure of the C-terminal domain of Vps28 reveals a conserved 
surface required for Vps20 recruitment. Traffic 7, 1007-1016.
Roessle, M. W., Klaering, R., Ristau, U., Robrahn, B., Jahn, D., Gehrmann, T., Konarev, 
P. V., Round, A., Fiedler, S., Hermes, S., and Svergun, D. I. (2007). Upgrade of the 
Small Angle X-ray scattering Beamline X33 at the EMBL Hamburg. J Appl 
Crystallogr 40, 190-194
Saksena, S., Sun, J., Chu, T., and Emr, S. D. (2007). ESCRTing proteins in the endocytic
pathway. Trends in Biochemical Sciences 32, 561-573.
Saksena, S., Wahlman, J., Teis, D., Johnson, A. E., and Emr, S. D. (2009). Functional 
reconstitution of ESCRT-III assembly and disassembly. Cell 136, 97-109.
Schmidt, M. H., Chen, B., Randazzo, L. M., and Bogler, O. (2003). SETA/CIN85/Ruk 
and its binding partner AIP1 associate with diverse cytoskeletal elements, including 
FAKs, and modulate cell adhesion. J Cell Sci 116, 2845-2855.
24
Schmidt, M. H., Hoeller, D., Yu, J., Furnari, F. B., Cavenee, W. K., Dikic, I., and Bogler, 
O. (2004). Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by 
the Cbl-SETA/CIN85 complex. Mol Cell Biol 24, 8981-8993.
Schoehn, G., El Bakkouri, M., Fabry, C. M., Billet, O., Estrozi, L. F., Le, L., Curiel, D. 
T., Kajava, A. V., Ruigrok, R. W., and Kremer, E. J. (2008). Three-dimensional 
structure of canine adenovirus serotype 2 capsid. J Virol 82, 3192-3203.
Shibata, H., Yamada, K., Mizuno, T., Yorikawa, C., Takahashi, H., Satoh, H., Kitaura, Y., 
and Maki, M. (2004). The penta-EF-hand protein ALG-2 interacts with a region 
containing PxY repeats in Alix/AIP1, which is required for the subcellular punctate 
distribution of the amino-terminal truncation form of Alix/AIP1. J Biochem (Tokyo)
135, 117-128.
Shim, S., Kimpler, L. A., and Hanson, P. I. (2007). Structure/Function Analysis of Four 
Core ESCRT-III Proteins Reveals Common Regulatory Role for Extreme C-Terminal 
Domain. Traffic 8, 1068-1079.
Strack, B., Calistri, A., Popova, E., and Gottlinger, H. (2003). AIP1/ALIX is a binding 
partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114, 689 - 699.
Suzuki, H., Kawasaki, M., Inuzuka, T., Okumura, M., Kakiuchi, T., Shibata, H., 
Wakatsuki, S., and Maki, M. (2008). Structural basis for Ca2+ -dependent formation of 
ALG-2/Alix peptide complex: Ca2+/EF3-driven arginine switch mechanism. Structure
16, 1562-1573.
Tanzi, G. O., Piefer, A. J., and Bates, P. (2003). Equine Infectious Anemia Virus Utilizes 
Host Vesicular Protein Sorting Machinery during Particle Release. J Virol 77, 8440-
8447.
Teis, D., Saksena, S., and Emr, S. D. (2008). Ordered assembly of the ESCRT-III 
complex on endosomes is required to sequester cargo during MVB formation. Dev 
Cell 15, 578-589.
Trioulier, Y., Torch, S., Blot, B., Cristina, N., Chatellard-Causse, C., Verna, J. M., and 
Sadoul, R. (2004). Alix, a protein regulating endosomal trafficking, is involved in 
neuronal death. J Biol Chem 279, 2046-2052.
Usami, Y., Popov, S., and Gottlinger, H. G. (2007). Potent rescue of human 
immunodeficiency virus type 1 late domain mutants by ALIX/AIP1 depends on its 
CHMP4 binding site. J Virol 81, 6614-6622.
Usami, Y., Popov, S., Popova, E., and Gottlinger, H. G. (2008). Efficient and Specific 
Rescue of Human Immunodeficiency Virus Type 1 Budding Defects by a Nedd4-like 
Ubiquitin Ligase. J Virol 82, 4898-4907.
Usami, Y., Popov, S., Popova, E., Inoue, M., Weissenhorn, W. and H, G.G. (2009) The 
ESCRT pathway and HIV-1 budding. Biochem Soc Trans, 37, 181-184.
Vito, P., Pellegrini, L., Guiet, C., and D'Adamio, L. (1999). Cloning of AIP1, a novel 
protein that associates with the apoptosis-linked gene ALG-2 in a Ca2+-dependent 
reaction. J Biol Chem 274, 1533-1540.
von Schwedler, U. K., Stuchell, M., Muller, B., Ward, D. M., Chung, H. Y., Morita, E., 
Wang, H. E., Davis, T., He, G. P., Cimbora, D. M., et al.(2003). The protein network 
of HIV budding. Cell 114, 701-713.
Weissenhorn, W. (2005). Crystal structure of the endophilin-A1 BAR domain. J Mol Biol
351, 653-661.
25
Welsch, S., Habermann, A., Jager, S., Muller, B., Krijnse-Locker, J., and Krausslich, H. 
G. (2006). Ultrastructural analysis of ESCRT proteins suggests a role for endosome-
associated tubular-vesicular membranes in ESCRT function. Traffic 7, 1551-1566.
Zamborlini, A., Usami, Y., Radoshitzky, S. R., Popova, E., Palu, G., and Gottlinger, H. 
(2006). Release of autoinhibition converts ESCRT-III components into potent 
inhibitors of HIV-1 budding. Proc Natl Acad Sci U S A 103, 19140-19145.
Zhai, Q., Fisher, R. D., Chung, H. Y., Myszka, D. G., Sundquist, W. I., and Hill, C. P. 
(2008). Structural and functional studies of ALIX interactions with YPX(n)L late 
domains of HIV-1 and EIAV. Nat Struct Mol Biol 15, 43-49.
Zhou, X., Pan, S., Sun, L., Corvera, J., Lee, Y. C., Lin, S. H., and Kuang, J. (2008a). The 
CHMP4b and Src docking sites in the Bro1 domain are autoinhibited in the native state 
of Alix. Biochem J. 418(2), 277-84.
Zhou, X., Pan, S., Sun, L., Corvera, J., Lin, S. H., and Kuang, J. (2008b). The HIV-1 
p6/EIAV p9 docking site in Alix is autoinhibited as revealed by a conformation-
sensitive anti-Alix monoclonal antibody. Biochem J. 414(2), 215-20.
26
Figure legends
Figure 1. ALIXforms monomers and dimers in solution. 
(A) ALIXBro1-V and (B) ALIXV, analyzed by MALLS indicates molecular weights of ~80 
and ~160 kDa for ALIXBro1-V and ~40 and ~80 kDa for ALIXV;left y-axis, refractive 
index; the molecular weight is blotted on the right axis in a logarithmic scale; x-axis 
shows the elution volume of the peaks. 
Figure 2. Small angle X-ray scattering analysis of ALIXBro1-V. (A) Experimental 
scattering intensity patterns obtained for monomeric (dark grey) and dimeric (light grey) 
ALIXBro1-V are shown as a function of resolution and after averaging and subtraction of 
solvent scattering. The scattering intensity patterns calculated from the ALIXBro1-V
monomer and dimer SAXS model 1&./!./(!>#1(2.!6!X4>A(!are shown as black lines.
(B) P(r) function of both monomeric (dark grey) and dimeric (light grey) ALIXBro1-V (both 
curves have been adjusted to the same height). The ab initio model envelope of 
monomeric ALIXBro1-V is shown together with the manually docked ALIXBro1-V structure 
(Fisher et al., 2007) as inset.
(C) Ab initio modeling of dimeric ALIXBro1-V reveals a crescent shape model spanning ~ 
270 Å; two orientations of the bead model including the molecular envelope are shown. 
Figure 3. Mapping of the conformational flexibility of ALIXBro1-V.
Hydrogen/deuterium (H/D) exchange labeling coupled to mass spectrometry analysis was 
used to determine conformational differences between monomeric and dimeric ALIXBro1-V. 
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(A) Example of local H/D exchange kinetic for the peptide sequence 637-648. The 
average mass (Mavg) is plotted against D2O incubation time. This reveals a difference in 
H/D exchange within this region where dimeric ALIXBro1-V shows less deuterium 
exchange compared to monomeric ALIXBro1-V over a period of 30 min. 
(B) The H/D exchange results have been plotted onto the structure of ALIXBro1-V (Fisher 
et al., 2007) and the differences in deuteration between monomer and dimer (!Mavg) are 
scored according to the following color code: green regions are more protected from H/D 
exchange in dimeric ALIXBro1-V while regions shown in red < orange < yellow are less 
accessible to H/D exchange within monomeric ALIXBro1-V. Regions in blue show similar 
accessibility between monomeric and dimeric ALIXBro1-V and regions in grey were not 
covered by peptide mapping of the deuterated forms.
Figure 4. Mutagenesis of the ALIXV dimer hinge region generates elongated ALIXV
monomers. 
(A) SEC reveals that ALIXVmut1 produces only one peak as compared to wild type ALIXV
and ALIXVmut2. 
(B) MALLS analyses show that ALIXVmut1 is monomeric and ALIXVmut2 exists in 
monomer and dimer conformations.  Both refractive index and molecular weight analyses 
(logarithmic scale) are plotted against the elution volume. The molecular weight 
distribution across each peak is indicated by dots. 
Figure 5. SAXS model of ALIXVmut1. (A) X-ray scattering curves of wild type ALIXV 
(red) and ALIXVmut1 (blue) is shown after averaging and subtraction of solvent scattering. 
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The inset shows the corresponding Guinier plots. The theoretical scattering profiles 
calculated from the ab initio '#%(>2!1&./!./(!>#1(2.!6!X4>A(2!4$(!2/#10!42!B>4)J!>&0(28
(B) P(r) functions of both wild type and mutant ALIXVmut1. (C) Ab initio calculated 
model of ALIXVmut1 reveals an elongated 170Å long rod-like structure; two orientations of 
the bead models plus envelopes (grey) rotated by 90º are shown. (D) The three helical 
bundle structure (red ribbon) of one arm of ALIXV fits into the molecular envelope of 
ALIXVmut1 and the second arm (blue) would fit after a rotation of ~ 140ºalong the ALIXV
hinge region.
(E) Model for dimeric ALIX. Dimerzation requires that ALIXV opens and allows anti-
parallel interaction of the ALIX V-domains arms.
Figure 6: ALIXBro1-V dimerizes in vivo. ALIXBro1-V was expressed using a split YFP 
expression system.  (A) Co-expression of both ALIXBro1-V YFP fusion protein halves in 
HEK293 cells resulted in complementation (right panel). ALIXBro1-V expression thus 
induces ALIXBro1-V dimerization in vivo. 
(B) Expression of CHMP4BOP-ALIX revealed inclusions partly localized along the plasma 
membrane (left panel).
(C) Co-expression of ALIXBro1-V YFP fusion constructs and CHMP4BOP-ALIX; red 
fluorescence CHMP4BOP-ALIX (left panel), green fluorescence dimeric ALIX (middle 
panel) and the lower panel show the co-localization: CHMP4BOP-ALIX recruits ALIXBro1-V 
dimers in vivo into large inclusions. Control staining with DAPI is shown in all panels. 
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Figure 7. ALIX dimerization is important for HIV-1 budding. HIV-1 particle release
detected upon expression of RFP-ALIXV-PRD wild type and the dimerization mutants.
(A) Expression of RFP-ALIXVmut1-PRD reverses the dominant negative effect observed for 
expression of wild type RFP-ALIXV-PRD. Lane 1, vector control; lane 2, wild type RFP-
ALIXV-PRD;lane 3, RFP-ALIXVmut1-PRD. Detection of extracellular Gag levels (virions, left 
panel) and intracellular Gag levels (right panels) are shown.  
(B) Expression of RFP-ALIXVmut2-PRD does not influence the dominant negative effect 
observed for expression of wild type RFP-ALIXV-PRD. Lane 1, vector control; lane 2, wild 
type RFP-ALIXV-PRD; lane 3, RFP-ALIXVmut2-PRD. 
(C) Expression levels of RFP-ALIXV-PRD are shown for wild type (lane 2) and RFP-
ALIXVmut1-PRD (lane 3) expression (lane 1, RFP vector expression control). 
Figure 8. ALIXBro1-V interacts with CHMP4 polymers in vitro. Sucrose gradient 
centrifugation analysis of monomeric (A) and dimeric (B) ALIXBro1-V, (C) MBP-
CHMP4BOP, (D) MBP-CHMP4BOP-ALIX, (E) CHMP4BOP-ALIX, (F) MBP-CHMP4BOP-ALIX
and monomeric ALIXBro1-V, (G) MBP-CHMP4BOP-ALIX and dimeric ALIXBro1-V, (H) 
Western blot detection of both MBP-CHMP4BOP-ALIX and ALIXBro1-V present in the 
bottom fraction of gradients F and G; (I) CHMP4BOP-ALIX and monomeric ALIXBro1-V, (J) 
CHMP4BOP-ALIX and dimeric ALIXBro1-V. (Protein bands migrating below the 50kDa 
marker protein correspond to MBP*(*; C, D, E, F, G, I, J)).
Figure 9. Electron microscopy analyses of CHMP4B !-ALIX and ALIXBro1-V
complexes. Negative staining EM images of (A) MBP-CHMP4BOP, (B) MBP-
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CHMP4BOP-ALIX, (C) CHMP4BOP-ALIX, (D) CHMP4BOP-ALIX - ALIXBro1-V (monomer) 
complexes, (E) CHMP4BOP-ALIX- ALIXBro1-V (dimer) complexes. (F) Cryo-electron 
microscopy image of CHMP4BOP-ALIX. (G) Cryo EM images of selected ring structures of 
CHMP4BOP-ALIX; (H) Ring-like structures revealing the potential repeating unit, marked 
by arrows (left panel, negative staining, right panel cryo image). (I) 5 panels of cryo EM 
images showing CHMP4BOP-ALIX - ALIXBro1-V (dimer) complexes. The length of one rung 
and the distance between rungs are indicated schematically in panel 2. The scale bars are 
50 nm (A), 100 nm (B-F, I) and 30 nm (G, H). 
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Experimental procedures
Protein expression and purification
ALIXBro1-V containing residues 1-714 were expressed as a GST fusion protein. in E. coli
BL21 (DE3)-RIL cells. Cells were harvested by centrifugation, suspended in buffer A 
(50mM Tris-HCl pH 8.0; 80mM NaCl and 2mM  -mercaptoethanol) and lysed by 
sonication in the presence of protease inhibitors (complete EDTA-free protease 
inhibitors, Pierce). The cleared supernatant was loaded onto a glutathione sepharose 
(Amersham Biosciences) column and the column was washed in buffer A followed by 
extensive washes in buffer A plus 1 M NaCl and 1 M KCl. GST was cleaved off 
overnight at 4º with Precission Protease (1:200 w/w) and ALIXBro1-V was purified on a Q-
sepharose column (Amersham Biosciences) in buffer A. A Superdex S200 gel filtration 
column (Pharmacia) was used as a final purification step in buffer B (20 mM Hepes pH 
8.0, 100 mM NaCl). Protein concentration was determined by absorbance at 280 nm in a 
denaturing buffer (6M guanidinium hydrochloride, 0,02M phosphate buffer pH 6.5). 
ALIXV, containing residues 355-714, was cloned into expression vector pGEX6P-2 using 
standard PCR methods. The sequence was confirmed by DNA sequencing. Protein 
expression was performed in Escherichia coli BL21 (DE3)-RIL (Invitrogen) and purified 
as described for ALIXBro1-V. 
CHMP4B!C and CHMP4B!C_ALIX were cloned into the expression Vector 
pBADM41 containing an N-terminal HIS-MBP tag. CHMP4B!C comprises amino acids 
(aa) 1-193 and CHMP4B!C_ALIX corresponds to aa 1-175 followed by a linker of 20 aa 
(SNSASDDASASASADEDASS) and CHMP4B residues 204-224. All constructs were 
verified by sequencing. Protein expression was performed in E. coli BL21 (DE3)-RIL 
cells (Invitrogen) at 37°C. Cells were lysed by sonication in buffer C (50 mM Tris·HCl, 
pH 8.0; 100 mM NaCl; 3 mM 2-mercaptoethanol) including complete EDTA-free 
protease inhibitors (Pierce). The cell lysate was cleared by centrifugation and loaded onto 
an amylose column (Amersham Biosiences). The column was sequentially washed with 
buffer C alone, buffer C plus 1 M NaCl, and buffer C plus 1 M KCl. Proteins were eluted 
by applying 10 mM Maltose in buffer C. MBP was removed by TEV protease cleavage. 
Size exclusion chromatography and multi-angle laser scattering
Size exclusion chromatography was performed with a Shodex Protein KW-804 HPLC 
column (300 mm x 8.0 mm). The column was equilibrated in buffer E (20 mM Tris pH 
7.5, 150 mM NaCl) and the runs were perform at 20 °C with a flow rate of 0.8 ml/min. 
Stokes’ radii were determined by calibrating the column with globular proteins of known 
Stokes’ radius. On-line detection was performed by multi-angle laser light scattering 
(MALLS) using a DAWN-EOS detector (Wyatt Technology Corp., Santa Barbara, CA) 
equipped with a laser emitting at 690 nm and by refractive index measurement using a 
RI2000 detector (Schambeck SFD). Light scattering intensities were measured at 
different angles relative to the incident beam, and analysis of the data was performed 
with the ASTRA software (Wyatt Technology Corp., Santa Barbara, CA). Weight-
averaged (Mw) molecular weights were obtained from the molecular weight distribution 
across the elution peak as described (Lata et al., 2008).
HIV-1 release assay.
The virus release assays were performed as described (Strack et al., 2003). Briefly, 293T 
cells (1.2 x 106) were cotransfected with 1. !"#!$%!&'(&)*+!,-./-!01/$203!45!&67-1, 
 !"#$#%&#'(#)*+,'-.#*/0-*..1!&#*1,2*-#314"#,50*#'-#67, !,#)*-.1'!.#'(#89:-ALIXV-PRD, as 
indicated. Virions were pelleted through 20% sucrose. Virions and cell lysates were 
analyzed by Western blotting for detection of Gag proteins by using the anti-HIV-1 CA 
antibody 183-H12-5C.
Mammalian expression constructs
ALIXBro1-V cDNA was cloned into pcDNA3.1 vectors that contained the N-terminal and 
C-terminal halves of YFP (Michnick et al., 2007). Single vectors and both vectors 
together were transfected into HEK293 cells using TransIT (Mirus) and OptiMem 
(Invitrogen) according to the manufacturer's instructions. For further details see SOM. 
For indirect immunofluorescence HEK293 cells expressing ALIX-YFP fusions 
were cultured on coverslips and fixed with 4% paraformaldehyde for 20 min at 4°C. The 
cover slips were further incubated with 100 mM glycine in PBS for 10min // 0.2% Triton 
X-100 in PBS for 7 min / blocking buffer (5 % glycerol, 2 % BSA, 0.2 % Tween20, 0.05 
% sodium-acide in PBS) for 20 min at RT. Nuclei were stained with DAPI slides were 
mounted in Mowiol for confocal microscopy analysis. 
HEK293 cells expressing CHMP4B and or ALIX-YFP were fixed as described 
above followed by the primary antibody (anti-flag rabbit antibody (Sigma)) incubation in 
blocking buffer for 1h at 20°C. Slides were washed three times with PBS, followed by 
the secondary antibody (Alexa596 coupled anti-rabbit goat antibody (Invitrogen) in 
blocking buffer) incubation at 20°C for 1h. After three washes with PBS, slides were 
analyzed by confocal microscopy. 
Hydrogen/deuterium (H/D) exchange mass spectrometry (MS)
For LC-MS analysis ALIX peptides obtained by protease digestions were loaded on a 
peptide MacroTrap column (Michrom Bioresources) and desalted using mobile phase A 
;<=<>?#;)@)A#B9C# .'47,1'!# 1!# 3 ,*-A# ('-# $# 61!#  ,#  # (4'3# - ,*# '(# ><<# %4@61!=# :*0,1"*#
separation was performed on a reverse phase C18 column (1mm 100mm, ID L; 
Interchrom) pre-equilibrated at 15% (v/v) ACN-0.03% (v/v) TFA in water using a 15 to 
40% linear gradient in mobile phase B (95% ACN (v/v) containing 0.03% TFA in water) 
in 45min (for LC-MS experiments) or in 80 min (for LC-MS/MS experiments) and a flow 
- ,*#'(#D<#%4@61!=#C44#EF-MS and LC-MS/MS analyses were carried out with valves, trap 
cartridges and columns cooled to ice-bath temperature to minimize deuterium back-
exchange. Peptide mapping (LC-MS/MS) were performed on an ion trap mass 
spectrometer (Esquire 3000+, Bruker Daltonics) connected to a two-pump HPLC system 
(Shimadzu). Local kinetics of H/D exchange on peptide fragments (LC-MS) were 
analyzed on a 6210 TOF LC-MS system (Agilent Technologies). The data were 
processed using the software packages Data Analysis 3.2 (Bruker Daltonics) and Analyst 
QS 1.1 (Applied Biosystems). The spectra of peptides before deuteration were compared 
to those obtained after H/D exchange. The sequence coverage of the peptide map 
obtained from the non-deuterated protein was 85%. The H/D exchange analyses were 
done on 31 peptides covering 57 % of the sequence.
Small Angle Scattering Data Collection and Analysis
Protein samples were prepared in 20 mM Hepes pH 8.0, 100 mM NaCl. Repetitive 
measurements of 180 sec at 15 °C of the same protein solution were performed in order 
to check for radiation damage. The data were normalized to the intensity of the incident 
beam; the scattering of the buffer was subtracted and the difference curves were scaled 
for concentration. Data processing was performed using the program package PRIMUS 
(Konarev et al., 2003). The forward scattering I(0) and the radius of gyration Rg were 
evaluated using the Guinier approximation (Guinier, 1939) assuming that at very small 
angles (s < 1.3/Rg) the intensity is represented by I(s) = I(0) exp(-(sRg)
2
/3). These 
parameters were also computed from the entire scattering patterns using the indirect 
transform package GNOM (Svergun, 1992), which also provide the distance distribution 
function p(r) of the particle ( ! "dssrsrsIrp #$ sin)(2)(  ). The molecular mass of ALIXBro1-V
and ALIXVmut1 were calculated by comparison with the forward scattering from the 
reference solution of bovine serum albumin (BSA). From this procedure a relative 
calibration factor for the molecular mass (MM) can be calculated using the known 
molecular mass of BSA (66kDa) and the concentration of the reference solution.
Low-resolution models of monomeric ALIXBro1-V, dimeric ALIXBro1-V and 
monomeric ALIXVmut1 were built by the program DAMMIN (Svergun, 1999), which 
represents the protein as an assembly of dummy atoms inside a search volume defined by 
a sphere of the diameter Dmax. Starting from a random model, DAMMIN employs 
simulated annealing to build a scattering equivalent model fitting the experimental data 
Iexp(s) to minimize discrepancy:




















where N is the number of experimental points, c a scaling factor and Icalc(sj) and  (sj) 
are the calculated intensity and the experimental error at the momentum transfer sj, 
respectively. Ten independent DAMMIN bead models for monomeric and dimeric 
ALIXBro1-V and for ALIXVmut1 were calculated. Final models of these proteins were 
obtained by superposition of the ten independent shape reconstructions for each protein 
by using the program packages DAMAVER (Volkov and Svergun, 2003) and 
SUBCOMP (Kozin and Svergun, 2001). For dimeric ALIXBro1-V ab initioshape models 
were calculated either without symmetry constrains or assuming a 2-fold symmetry axis. 
For the symmetric models, ten DAMMIN models were obtained, superimposed and 
averaged. The overall envelope, especially the crescent-shape of dimeric ALIXBro1-V was 
the same for both unconstrained and constrained models. 
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Supplementary Figures
Figure S1:
Local H/D exchange kinetic for peptides derived from the Bro1 domain. The average 
mass is plotted against the D2O incubation time. These peptide regions demonstrate an 
increase in deuterium exchange in the ALIXBro1-V dimer as compared to the monomer.
Figure S2
Cryo EM image of CHMP4BGF-ALIX. Magnification of figure 9F. Scale bar is 100 nm.
Figure S3
Cryo EM images of CHMP4BGF-ALIX - ALIXBro1-V (dimer) complexes revealing mostly 
ladder-like structures.
